Abbott Laboratories

Equities

ABT

US0028241000

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:02 2024-12-12 pm EST			5-day change	1st Jan Change
113.86 ^USD	-0.25%		-1.82%	+3.44%

Dec. 12	Nephron Adjusts Price Target on Abbott Laboratories to $120 From $118	MT
Nov. 25	Abbott Announces First Step Toward Its Software-Guided Balloon-Expandable TAVI System to Treat Aortic Stenosis	CI

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

February 16, 2024 at 10:19 am EST

The board of directors of Abbott declared a quarterly common dividend of 55 cents per share. The cash dividend is payable May 15, 2024, to shareholders of record at the close of business on April 15, 2024.

Latest news about Abbott Laboratories

Nephron Adjusts Price Target on Abbott Laboratories to $120 From $118	Dec. 12	MT
Abbott Announces First Step Toward Its Software-Guided Balloon-Expandable TAVI System to Treat Aortic Stenosis	Nov. 25	CI
Insulet Corporation Announces Omnipod® 5 System Now Compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the U.S	Nov. 20	CI
Abbott Opens Global Manufacturing Facility in Kilkenny, Ireland	Nov. 18	CI
UK regulator flags concerns and remedies for sale of baby formula	Nov. 08	RE
Barclays Adjusts Price Target on Abbott Laboratories to $149 From $143	Nov. 04	MT
Barclays Adjusts Abbott Laboratories Price Target to $149 From $143	Nov. 04	MT
Health Care Up on Defensive Demand -- Health Care Roundup	Nov. 01	DJ
Reckitt, Abbott Shares Rise After Baby-Formula Lawsuit Win -- Update	Nov. 01	DJ
Abbott Laboratories Found Not Responsible for Boy's Intestinal Disease by Missouri Jury in Baby Formula Trial	Nov. 01	MT
Abbott shares rise after securing first win in premature infant formula trial	Nov. 01	RE
North American Morning Briefing : Tech Steadies as Traders Await Jobs Report	Nov. 01	DJ
Reckitt Shares Surge After Baby Formula Lawsuit Win	Nov. 01	DJ
Shares in Reckitt Benckiser leap amid Mead Johnson legal win	Nov. 01	AN
Stocks to Watch : Intel, Amazon.com, Abbott Laboratories, MasTec	Oct. 31	DJ
Abbott Laboratories Shares Rise After Baby-Formula Verdict	Oct. 31	DJ
Tranche Update on Abbott Laboratories's Equity Buyback Plan announced on December 10, 2021.	Oct. 31	CI
Abbott Laboratories Launches Clinical Study of Early Heart Pump Intervention in Heart Failure	Oct. 24	MT
Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure	Oct. 24	CI
Abbott Laboratories Insider Sold Shares Worth $18,424,298, According to a Recent SEC Filing	Oct. 23	MT
Daiwa Securities Adjusts Price Target on Abbott Laboratories to $125 From $120	Oct. 23	MT
Argus Adjusts Price Target on Abbott Laboratories to $145 From $135	Oct. 21	MT
Abbott Laboratories Strategizing 'Price Wars' With CGM Flexibility, Oppenheimer Says	Oct. 17	MT
Abbott Laboratories' Q3 Results Show Strength of Diversified Business Model, RBC Says	Oct. 17	MT
UBS Adjusts Price Target on Abbott Laboratories to $146 From $143, Maintains Buy Rating	Oct. 17	MT

Chart Abbott Laboratories

Duration

Period

ABT: Dynamic Chart

Company Profile

Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).

Employees

114,000

Sector

Medical Equipment, Supplies & Distribution

Calendar

2025-01-21 - Q4 2024 Earnings Release (Projected)

More about the company